MetaCap

Aura Biosciences (AURA) vs DBV Technologies S.A. (DBVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Aura Biosciences is the larger company by market cap ($669.9 million vs $614.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

AURA versus DBVT key metrics
MetricAURADBVT
Share price$6.46$9.77
Market cap$669.93M$614.03M
1-day change+4.70%-2.10%
YTD return+18.53%—
1-year return+12.15%—
EPS (TTM)$-1.75$-3.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$9.54$26.19
52-week low$4.73$9.64
Distance from 52-week high-32.25%-62.69%
Average volume748.04K325.32K
Shares outstanding103.70M62.85M
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

AURA vs DBVT FAQ

Which is bigger, Aura Biosciences or DBV Technologies S.A.?

Aura Biosciences (AURA) is larger, with a market capitalization of $669.93M compared with $614.03M for DBV Technologies S.A. (DBVT).

Are Aura Biosciences and DBV Technologies S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons